Pseudo progression in heterogeneity of right-sided metastatic colon carcinoma during nivolumab therapy: A case report

AbstractRationale:Pseudo progression is a noted phenomenon of immune checkpoint inhibitors therapy, which has been defined as a response after an initial enlargement of the tumor followed by tumor reduction. In July 2017, the Food and Drug Administration granted accelerated approval of nivolumab for